StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Equities researchers at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

NASDAQ LPCN opened at $3.01 on Wednesday. Lipocine has a 12 month low of $2.75 and a 12 month high of $11.79. The stock has a market cap of $16.10 million, a PE ratio of -3.96 and a beta of 1.51. The stock’s 50 day moving average is $3.24 and its 200 day moving average is $4.32.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC raised its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the period. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.